In­tel­lia, Verve run clin­i­cal tri­als abroad amid FDA’s ‘cau­tious’ ap­proach to gene edit­ing

In­tel­lia Ther­a­peu­tics an­nounced ear­li­er this month that it would run a mid-stage tri­al of a CRISPR-based treat­ment for a rare ge­net­ic dis­ease called hered­i­tary an­gioede­ma …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER